SWOG clinical trial number
CTSU/EA1131
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy
Open
Phase
Abbreviated Title
Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative BC following Neoadjuvant Chemotherapy
Status Notes
ECOG-ACRIN activated: 4/29/2015
SWOG activated: 7/24/19
SWOG activated: 7/24/19
Activated
07/24/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Breast Cancer
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).
Other Clinical Trials
SWOG Clinical Trial Number
S2007
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Research Committee(s)
Breast Cancer
Activated
12/15/2020
Accrual
0%
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA1131
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy
Research Committee(s)
Breast Cancer
Activated
07/24/2019
Open
Phase
SWOG Clinical Trial Number
CTSU/A011202
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Research Committee(s)
Breast Cancer
Activated
07/24/2019
Open
Phase